NCT00975806View on ClinicalTrials.gov

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 1, 2009

Primary Completion Date

October 1, 2011

Study Completion Date

October 1, 2011

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Lenalidomide

Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination

DRUG

Sunitinib

Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G

Trial Locations (3)

37203

Tennessee Oncology, Nashville

44195

Cleveland Clinic Main Campus, Cleveland

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY